Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger Stupp

Showing results (181-190 of 314) with videos related to

Pageof 32
Sort By:
The Lancet. Oncology|December 3, 2005
Health-related quality of life in patients with glioblastoma: a randomised controlled trialMartin J B Taphoorn, Roger Stupp, Corneel Coens, et al.
Neuro-Oncology|October 24, 2012
EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastomaEnrico Franceschi, Roger Stupp, Martin J van den Bent, et al.
Journal of Neuro-Oncology|June 12, 2024
Long-term outcomes of central neurocytoma - an institutional experienceYufan Yang, Nitin Wadhwani, Aoi Shimomura, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2024
Paclitaxel and Carboplatin in Combination with Low-intensity Pulsed Ultrasound for GlioblastomaKarl J Habashy, Crismita Dmello, Li Chen, et al.
European Journal of Cancer (Oxford, England : 1990)|April 3, 2012
New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trialsThierry Gorlia, Roger Stupp, Alba A Brandes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2010
Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98Giovanni Martinelli, Shu-Fang Hsu Schmitz, Urs Utiger, et al.
BMC Cancer|January 17, 2013
A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumorsJoseph P Connor, Mihaela C Cristea, Nancy L Lewis, et al.
Journal of Clinical Apheresis|March 23, 2016
Efficacious and save use of biosimilar filgrastim for hematopoietic progenitor cell chemo-mobilization with vinorelbine in multiple myeloma patientsJulia-Tatjana Maul, Frank Stenner-Liewen, Burkhardt Seifert, et al.
Oncotarget|September 15, 2016
PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation statusKenney R Roodakker, Tamador Elsir, Per-Henrik D Edqvist, et al.
Advances in Oncology|October 20, 2023
Advances in Blood-Brain Barrier Disruption to Facilitate Drug Delivery for Infiltrative GliomasAndrew Gould, Victor Andrés Arrieta Gonzales, Crismita Clement Dmello, et al.
Pageof 32

Showing results (181-190 of 314) with videos related to

Sort By:
Pageof 32
The Lancet. Oncology|December 3, 2005
Health-related quality of life in patients with glioblastoma: a randomised controlled trialMartin J B Taphoorn, Roger Stupp, Corneel Coens, et al.
Neuro-Oncology|October 24, 2012
EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastomaEnrico Franceschi, Roger Stupp, Martin J van den Bent, et al.
Journal of Neuro-Oncology|June 12, 2024
Long-term outcomes of central neurocytoma - an institutional experienceYufan Yang, Nitin Wadhwani, Aoi Shimomura, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2024
Paclitaxel and Carboplatin in Combination with Low-intensity Pulsed Ultrasound for GlioblastomaKarl J Habashy, Crismita Dmello, Li Chen, et al.
European Journal of Cancer (Oxford, England : 1990)|April 3, 2012
New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trialsThierry Gorlia, Roger Stupp, Alba A Brandes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2010
Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98Giovanni Martinelli, Shu-Fang Hsu Schmitz, Urs Utiger, et al.
BMC Cancer|January 17, 2013
A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumorsJoseph P Connor, Mihaela C Cristea, Nancy L Lewis, et al.
Journal of Clinical Apheresis|March 23, 2016
Efficacious and save use of biosimilar filgrastim for hematopoietic progenitor cell chemo-mobilization with vinorelbine in multiple myeloma patientsJulia-Tatjana Maul, Frank Stenner-Liewen, Burkhardt Seifert, et al.
Oncotarget|September 15, 2016
PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation statusKenney R Roodakker, Tamador Elsir, Per-Henrik D Edqvist, et al.
Advances in Oncology|October 20, 2023
Advances in Blood-Brain Barrier Disruption to Facilitate Drug Delivery for Infiltrative GliomasAndrew Gould, Victor Andrés Arrieta Gonzales, Crismita Clement Dmello, et al.
Pageof 32